Sanofi, a France-based multinational pharmaceutical company, is investing EUR80m in equity in BioNTech, which is claimed to be Europe's largest privately-held biopharmaceutical firm focused on the development of individualised therapies for cancer and the prevention of infectious diseases, it was reported yesterday.
According to the contract, BioNTech is eligible to receive USD60m in upfront and near-term milestone payments. The firm is also eligible to receive more than USD300m in development, regulatory and commercial milestones and other payments per product.
The company has the option to co-develop and co-commercialiSe two of the five mRNA therapeutics products with Sanofi in the European Union and the United States.
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval